" Algernon Pharmaceuticals (CSE:AGN) completes manufacturing of DMT and appoints UK stroke experts for phase 2 trials
Algernon Pharmaceuticals (AGN) has manufactured a supply of clinical-grade AP-188 DMT for its planned phase 1 and phase 2 clinical trials.
" PharmaDrug (CSE:PHRX) advances psychedelics program to treat eye diseases
PharmaDrug Inc. (PHRX) announced Terasaki Institute for Biomedical Innovation (TIBI) will begin in vitro studies on a short-list of DMT analogue molecules.
" Algernon (CSE:AGN) files meeting request with the MHRA for use of DMT in human stroke study
Algernon Pharmaceuticals (AGN) has filed a scientific advice meeting request with the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA).
" Algernon Pharmaceuticals (CSE:AGN) receives positive feedback from U.S. FDA for its DMT clinical research program
Algernon Pharmaceuticals (AGN) has received positive feedback from the FDA regarding its DMT stroke clinical research program.